# Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

> **NCT00216203** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nasser Hanna, M.D.** · enrollment: 36 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00216203
- **Lead sponsor:** Nasser Hanna, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216203, "Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00216203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*